Browsing: Aptorum Group Limited

Aptorum Group Joins the BEAM Alliance To Combat Antimicrobial Resistance

By Marie JonesSeptember 8, 20200

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group”), a biopharmaceutical company focused on novel therapeutics including the development…

HealthCare

Aptorum Group to Hold Investor Webinar and Present at The Wall Street Investor Forum on September 10

By Marie JonesSeptember 8, 20200

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel therapeutics including…

BioTech

Aptorum Group Announces Further Positive Data on ALS-4 against MRSA Wound Infection and MRSA Bacteraemia against Linezolid and Vancomycin Respectively in In Vivo Models

By Marie JonesSeptember 1, 20200

Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group”), a biopharmaceutical company focused on novel therapeutics including the development…

BioTech

Aptorum Group Announces Further Positive Data on SACT-1 Against Neuroblastoma and Other Potential Tumor Types

By Marie JonesSeptember 1, 20200

Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics…

BioTech

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2020

By Marie JonesSeptember 1, 20200

Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group”or the “Company”), a biopharmaceutical company focuses on the development of…